ResMed Jumps On Board As Nyxoah Raises €25m For Neurostim Apnea Device
Executive Summary
The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.